Home / Weight & metabolism / Mazdutide
MaApproved drug

Mazdutide

Mazdutide is a weekly injection that works on two gut hormone receptors, GLP-1 and glucagon. China approved it for weight management in June 2025. It is made by Innovent.

Approved in China for chronic weight management (NMPA, June 2025)No US FDA or EMA approval found9 mg dose: phase 3 positive, approval not confirmed
OverviewDosingMixingResearchCommunitySafetyFAQSources

Mazdutide quick reference

TypeGLP-1 and glucagon dual agonist
Studied forWeight loss, type 2 diabetes
EvidencePhase 3; approved in China
RouteInjection under the skin
Half-lifeSupports weekly dosing

What is Mazdutide?

Weekly injection that hits GLP-1 and glucagon receptors.

Used for weight loss and blood sugar control.

Approved in China (2025). No US or EU approval found.

How Mazdutide works

GLP-1 receptor

Lowers appetite and helps insulin release.

Glucagon receptor

Adds an energy-use and liver pathway.

Step-up dosing

Doses rise over weeks to ease stomach effects.

What Mazdutide is studied for

PeopleWeight loss, 4 and 6 mg

Lost 11% and 14% in 48 weeks (China).

PeopleWeight loss, 9 mg

Lost 16.7% in 60 weeks (China).

PeopleHigher doses, US

10 and 16 mg gave 15.6% and 18.1% loss by week 32.

PeopleType 2 diabetes

Beat dulaglutide on HbA1c and weight at 28 weeks.

Mazdutide dosing protocol

Weeks (GLORY-1)Weekly amount
1-42 mg (both groups)
5-84 mg (both groups)
9-484 mg group stays on 4 mg; 6 mg group goes up to 6 mg
GLORY-2 (60 weeks)9 mg target; the step-up plan was not in the sources I checked

GLORY-1 schedule is from the ClinicalTrials.gov entry NCT05607680. The 4 mg group was 2 mg for 4 weeks, then 4 mg for 44 weeks. The 6 mg group was 2 mg, 4 mg, then 6 mg for 40 weeks. This is a trial schedule. The Chinese label was not read, so check it for the exact approved doses.

TRIAL 4 MG PLAN2 mg x4 wk, then 4 mg x44 wkTrial
TRIAL 6 MG PLAN2 mg, 4 mg, then 6 mg x40 wkTrial
TRIAL HIGH DOSE9 mg weekly for 60 weeksTrial
US PHASE 23 to 6 mg, 10 mg or 16 mg weeklyTrial
COMMUNITY RANGE4-6 mg weeklyCommunity

Label and trial amounts come from the sources below. Community amounts are what people report; they have not been tested.

Mixing

Vial10 mg
+
BAC water2 mL
=
Strength5 mg per mL

Common example. Add BAC water slowly, swirl, keep cold.

Open the peptide calculator

What the research found

GLORY-1: 610 adults in China with overweight or obesity, 48 weeks. GLORY-2: 461 adults with obesity, 60 weeks. Average body weight change (treatment-policy analysis):

-14.0%6 mg, week 48 (GLORY-1)
-11.0%4 mg, week 48 (GLORY-1)
-16.7%9 mg, week 60 (GLORY-2)
+0.3% / -1.5%Placebo (GLORY-1 / GLORY-2)

Ji L et al. N Engl J Med 2025 (GLORY-1, NCT05607680). JAMA 2026 (GLORY-2, NCT06164873). Both trials were in Chinese adults, so results may differ elsewhere.

Mazdutide community experience

What users report. Not tested in trials.

Positive reports

  • Appetite drop GLP-1 action makes less hunger the main report.
  • Different feel Users compare the glucagon arm with tirzepatide.
  • Easy to track Weight, waist and intake are simple to follow.

Negative & mixed

  • Stomach upset Nausea and diarrhea cloud early weight changes.
  • Unverified vials Reports cannot confirm trial-grade material.
  • Shaky rankings Different trials make head-to-head claims unreliable.

Mazdutide stacking

Mazdutide + retatrutide

Retatrutide adds GIP. Not studied together.

Mazdutide + tirzepatide

Both already strong. Not studied together.

Mazdutide side effects & safety

Common

  • Vomiting: 53% on 9 mg, 1% placebo.
  • Nausea: 47% on 9 mg, 3% placebo.
  • Diarrhea: 39% on 9 mg, 6% placebo.
  • Most events mild to moderate.
  • Less appetite can make eating enough harder.

Less common

  • Quit for side effects: 2.9% on 9 mg.
  • Up to 20% quit on 16 mg in US phase 2.
  • Long-term outcomes are not yet known.

Precautions

  • Pregnancy or breastfeeding: ask a doctor first.
  • Insulin or sulfonylureas: sugar can drop; doses may need change.
  • Persistent vomiting or diarrhea can cause dehydration.
  • Severe belly pain needs urgent care.

Our verdict on Mazdutide

Real phase 3 weight-loss data and a China approval. Stomach effects are the main cost.

Mazdutide FAQ

Is mazdutide approved?

In China since 2025, for weight management. Not in the US or EU.

How much weight loss?

11% on 4 mg and 14% on 6 mg at 48 weeks.

How is it different from tirzepatide?

It adds glucagon, not GIP, to GLP-1.

Sources

  • Ji L et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med 2025 (GLORY-1), NCT05607680
  • Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity (GLORY-2). JAMA 2026, NCT06164873
  • ClinicalTrials.gov NCT05607680 (arm schedule)
  • Innovent press release via PR Newswire / PharmaFocus Asia, 30 June 2025 (NMPA approval for chronic weight management in adults with BMI 28+ or 24+ with a related condition)
  • Efficacy and safety of mazdutide in adults with obesity or overweight: US phase 2 trial. Lancet Diabetes Endocrinol 2026, NCT06124807 (PubMed 42628555)
  • Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature 2026 (PubMed 41407860)